Sobi to Buy Arthrosi Therapeutics for Up to $1.5 Billion

05:33 AM EST, 12/14/2025 (MT Newswires) -- Swedish Orphan Biovitrum (SOBI.ST), or Sobi, agreed to purchase fellow biotechnology company Arthrosi Therapeutics, according to a Dec. 13 release. The transaction comprises an upfront cash consideration of $950 million, as well as sales, clinical, and regulatory milestone payments worth up to $550 million. Sobi noted that the acquisition is set to boost its gout portfolio with the addition of Arthrosi Therapeutics's pozdeutinurad oral URAT1 inhibitor into its offering. Closing of the deal is expected in the first half of 2026, subject to customary requirements.